Natasha Hernday
CIK 1780547 · last filed 2026-07-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$332.1K
Companies
5
Total Filings
21
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XOMA | Director | 0 | $40.17 | $0 | $0 | 2 | 2026-07-14 |
| JANX | Director | 15,481 | $15.00 | $232.2K | $0 | 4 | 2026-06-12 |
| XOMAP | Director | 4,000 | $24.98 | $99.9K | $0 | 7 | 2026-05-26 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | — | $64.97 | — | $0 | 6 | 2024-05-20 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 75,826 | — | — | $0 | 2 | 2020-08-24 |
Recent Filings · Page 2 of 3
21 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-19 | XOMAP | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-20 | XOMAP | Grant (A) | — | $0 | EDGAR |
| 2022-01-04 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | XOMAP | Grant (A) | — | $0 | EDGAR |
| 2021-01-05 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-17 | XOMAP | Grant (A) | +4,000 | $100.0K | EDGAR |
| 2020-12-11 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-24 | PDL BIOPHARMA, INC. (PDLI) Delisted | Grant (A) | +25,826 | $0 | EDGAR |
| 2020-07-02 | XOMA | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.